The breakthrough could be “basis for a new generation of anti-degeneration drugs.”
Key aspects of the ageing of human cells can be reversed by new compounds developed at the University of Exeter, research shows.
In a laboratory study of endothelial cells – which line the inside of blood vessels – researchers tested compounds designed to target mitochondria (the “power stations” of cells).
In the samples used in the study, the number of senescent cells (older cells that have deteriorated and stopped dividing) was reduced by up to 50%.
The Exeter team also identified two splicing factors (a component of cells) that play a key role in when and how endothelial cells become senescent. The findings raise the possibility of future treatments not only for blood vessels – which become stiffer as they age, raising the risk of problems including heart attacks and strokes – but also for other cells.
“As human bodies age, they accumulate old (senescent) cells that do not function as well as younger cells,” said Professor Lorna Harries, of the University of Exeter Medical School.
“This is not just an effect of ageing – it’s a reason why we age.
“The compounds developed at Exeter have the potential to tweak the mechanisms by which this ageing of cells happens. We used to think age-related diseases like cancer, dementia and diabetes each had a unique cause, but they actually track back to one or two common mechanisms. This research focuses on one of these mechanisms, and the findings with our compounds have potentially opened up the way for new therapeutic approaches in the future.
“This may well be the basis for a new generation of anti-degenerative drugs.”
Professor Harries said the goal was to help people stay healthier for longer. She added: “This is about health span and quality of life, rather than merely extending lifespan.”
In a paper published last year, the team demonstrated a new way to rejuvenate old cells in the laboratory. However, the new research looked at precisely targeting and rejuvenating mitochondria in old cells. Each one of our genes is capable of making more than one product, and splicing factors are the genes that make the decision about which of these products are made.
In this new work, using novel chemicals, the researchers were able to very specifically target two splicing factors (SRSF2 or HNRNPD) that play a key role in determining how and why our cells change with advancing age.
“Nearly half of the aged cells we tested showed signs of rejuvenating into young cell models,” said Professor Harries.
The researchers tested three different compounds, all developed at the University of Exeter, and found each produced a 40-50% drop in the number of senescent blood vessel cells.
The compounds in question – AP39, AP123 and RT01 – have been designed by the Exeter team to selectively deliver minute quantities of the gas hydrogen sulfide to the mitochondria in cells and help the old or damaged cells to generate the ‘energy’ needed for survival and to reduce senescence.
“Our compounds provide mitochondria in cells with an alternative fuel to help them function properly,” said Professor Matt Whiteman, also from the University of Exeter.
“Many disease states can essentially be viewed as accelerated ageing, and keeping mitochondria healthy helps either prevent or, in many cases using animal models, reverse this.
“Our current study shows that splicing factors play a key role in determining how our compounds work.”
The Latest on: Anti-degeneration drugs
via Google News
The Latest on: Anti-degeneration drugs
- Clene Nanomedicine's RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MNDon December 7, 2021 at 4:04 am
Late-breaker oral presentation by Professor Steve Vucic, University of Sydney Medical School and Northcott Chair of Neurology CNM-Au8® demonstrated significantly slowed disease progression: decreased ...
- Advances in Macular Degeneration From AAO 2021on December 6, 2021 at 6:58 am
Studies at AAO 2021 highlighted advances in a variety of wet macular degeneration therapies that would reduce treatment burden while preserving vision comparably to monthly in-office injections.
- Can Air Pollution Cause Vision Loss? Expert Answerson December 6, 2021 at 4:37 am
As per a UK biobank study, air pollution is associated with an increased risk of progressive and irreversible sight loss, known as age related macular degeneration (AMD).
- Ask the expert: what is age-related macular degeneration (AMD)?on December 2, 2021 at 10:12 am
Age-related macular degeneration (AMD) is one of the most common causes of blindness in the UK and the leading cause of sight loss in those aged 55 and over. Raising awareness of the signs and ...
- Macular Therapeutics receives 3 US patents for methods to treat macular degeneration using botulinum-based neuromodulatorson December 2, 2021 at 2:30 am
Macular Therapeutics receives 3 US patents for methods to treat macular degeneration using botulinum-based neuromodulators: Boston Thursday, December 2, 2021, 16:00 Hrs [IST] Macu ...
- TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in Chinaon December 1, 2021 at 4:11 pm
TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical ...
- Advice From an Ophthalmologist: What You Need to Know About Wet Age-Related Macular Degenerationon December 1, 2021 at 4:00 pm
A wet AMD diagnosis leaves you with lots (and lots) of questions. Forget Dr. Google. We asked an expert to weigh in.
- Isarna Therapeutics Announces First Patient Enrolled in International Phase 2a Clinical Study in Ophthalmology Indications Wet AMD and DMEon December 1, 2021 at 12:36 am
Isarna Therapeutics today announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients ...
- Macular Therapeutics, Inc. Announces Issuance of Three U.S. Patents for Methods to Treat Macular Degeneration Using Botulinum-Based Neuromodulatorson November 30, 2021 at 9:05 am
Macular Therapeutics, Inc., (MCT) a private biotechnology company targeting neuromodulation and molecular-guided tissue remodeling to stabilize cellul ...
via Bing News